LY 2389575 hydrochloride
目录号 : GC14722negative allosteric modulator of mGlu3
Cas No.:885104-09-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
LY2389575 is described here instead of LY2389575 hydrochloride. LY2389575 is a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 3 (mGlu3) with an IC50 value of 4.2 μM [1].
The metabotropic glutamate receptors (mGlus) are members of the GPCR family C. They are characterized by a large extracellular amino-terminal domain for binding agonist. Eight mGlus had been found and were assigned to three groups based on their pharmacology, sequence homology, and mechanisms to couple to effector. They are Group I: mGlu1 and mGlu5; Group II: mGlu2 and mGlu3; Group III: mGlu4,6,7,8 [1].
In mixed neuronal cultures, LY2389575 abolished the protective activity of 1 μM LY379268 (the orthosteric mGlu2/3 receptor agonist) in the concentration range of 0.1 to 1 μM and amplified Aβ toxicity on its own at the highest concentration. In the absence of Aβ, LY2389575 at these concentrations was not toxic (numbers of dead neurons in control cultures and in cultures treated with 1 μM LY2389575 were 41 ± 3, and 42 ± 1, respectively). Further data indicated that LY2389575 was able to amplify Aβ toxicity and abolish the neuroprotective activity of LY379268 only in cultures containing wild-type astrocytes. In the FLIPR assay system, LY2389575 behaved as a noncompetitive mGlu3 receptor antagonist with an efficacy of 100 ± 0.68% and an IC50 value of 190 ± 26 nM. LY2389575 failed in affecting responses mediated by all other mGlu receptor subtypes or GABAB receptors [2].
No in vivo data for the application of this drug had been found.
References:
[1]. Sheffler DJ, Wenthur CJ, Bruner JA, et al. Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM[J]. Bioorganic & medicinal chemistry letters, 2012, 22(12): 3921-3925.
[2]. Caraci F, Molinaro G, Battaglia G, et al. Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer's Disease: Selective Activation of mGlu2 Receptors Amplifies β-Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is Neuroprotective[J]. Molecular pharmacology, 2011, 79(3): 618-626.
Cas No. | 885104-09-6 | SDF | |
化学名 | (S)-1-(5-bromopyrimidin-2-yl)-N-(2,4-dichlorobenzyl)pyrrolidin-3-amine hydrochloride | ||
Canonical SMILES | BrC1=CN=C(N2CC[C@@](NCC3=C(Cl)C=C(Cl)C=C3)([H])C2)N=C1.Cl | ||
分子式 | C15H15BrCl2N4.HCl | 分子量 | 438.58 |
溶解度 | <8.77mg/ml in DMSO | 储存条件 | Desiccate at RT |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.2801 mL | 11.4004 mL | 22.8009 mL |
5 mM | 0.456 mL | 2.2801 mL | 4.5602 mL |
10 mM | 0.228 mL | 1.14 mL | 2.2801 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。